Possible Mechanisms of Cancer Drug Resistance in Multiple Myeloma Therapeutics Resistance Mechanism Mutations of proteins in CRBN-IK axis associated with deficient expression PI Amplified expression of P-gp/ABCB1 and MRP1/ABCC1 MoAb Low expression level of target antigen; upregulation of the complemen...
In addition to direct clinical application in the choice of best treatment, this tool was also used to study changes in sensitivity of patient tumors to other drugs, and it was iv observed that, upon relapse, in addition to developing resistance to the current line of therapy, tumors become ...
Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several conjugates successfully translated into clinical practice. The conjugation of therapeutic agents to polymeric carriers, such as polyethylene glycol, offers severa
What factors influence your choice for treating with approved agents vs enrolling your patient in a clinical trial? How does your treatment approach vary based on histology? Sahu: Isn’t papillary the most common nccRCC variant? McGregor: Yes, papillary is about 80% of the diver...
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database Article Open access 25 April 2024 Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study ...
The device must be cared for in accordance with the international evidence base. This should include choice of dressing, solution used for site care during dressing changes, and length of time the device is left in situ. Three-way taps should not be used, as they act as a reservoir for ...
In the field of drug discovery, assessing the potential of multidrug therapies isa difficult task because of the combinatorial complexity (both theoretical andexperimental) and because of the requirements on the selectivity of the therapy.To cope with th
Two strategies are applied to construct drug delivery systems: one is to use delivery carriers to improve the stability of the drug, and the other is a prodrug strategy in which the drug is covalently modified to temporarily limit the activity of the drug. Compared with the former, the ...
Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media. By accepting optional cookies, you consent to the processing of your personal data - including ...
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic agents, potentially reducing the severity of side effects by preferentially targeting their payload to the tumour site. ADCs are being increasingly used in combination with other agents,...